Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

Abstract

Median survival of the middle-aged group (45-60 years) was significantly longer than the young group (<45 years) and the old group (>60 years). Therefore, aggressive treatment modalities should be strongly considered for young lung cancer patients.